Valneva's Strategic Pivot: Job Cuts and Pipeline Progress Offer Glimmers Amid Steep Stock Decline
14.06.2026 - 14:17:28 | boerse-global.de
Valneva is hacking away at its cost base with a global workforce reduction of 10 to 15 percent, targeting a 25 to 35 percent drop in operating expenses versus last year. The moves come as the stock wallows near €2.27, having shed nearly 41 percent since January. Management is now touring Europe and the US to shore up investor confidence before the annual meeting later this month.
The restructuring was triggered by a brutal first quarter. Revenue collapsed 37.2 percent year-on-year to €30.9 million, while the net loss widened to €32.1 million. The company also trimmed its full-year product sales forecast to between €135 million and €150 million, down from an earlier range of €145 million to €160 million. Sluggish demand for travel vaccines, blamed on geopolitical headwinds, lies behind the downgrade.
Yet the clinical pipeline offers a counterpoint to the operational gloom. The Lyme disease candidate LB6V, developed with Pfizer, posted Phase 3 efficacy of 73.2 to 74.8 percent against confirmed cases — comfortably above the pre-specified lower confidence bound of 20 percent that had caused concern after the first analysis. Pfizer intends to file a Biologics License Application with the FDA and a Marketing Authorization Application with the EMA in 2026. No Lyme vaccine has been approved in the US since 2002, underscoring the commercial potential. Separately, Valneva's four-valent Shigella vaccine S4V2, which secured FDA Fast-Track status in October 2024, is on track for its first Phase 2 data readout by mid-2026. The global market for Shigellosis vaccines is estimated at more than $500 million annually.
Should investors sell immediately? Or is it worth buying Valneva?
Cash reserves stood at €105.3 million at the end of March — a cushion that buys time but not complacency. The annual general meeting convenes in Lyon on June 25, with shareholders asked to formally approve a three-year extension of CEO Thomas Lingelbach's mandate. The supervisory board has already signed off, but the vote remains a moment of focus.
Technically, the stock is stretched. It trades about 56 percent below its 52-week high of €5.16 and nearly 9 percent below its 50-day moving average. The relative strength index of 38.3 signals oversold conditions, though no reversal pattern has yet emerged. Key support lies at the 52-week low of €2.13, while the long-term trendline at €3.70 offers a distant resistance. Adding to the pressure, the Federal Reserve's June rate decision and the Eurozone's latest inflation print of 3.2 percent weigh on risk appetite across biotech.
Three events now converge over the next month: Pfizer’s formal regulatory timeline for LB6V, the S4V2 data update, and the AGM. Should any of these catalysts land positively, analysts expect the shares to break out of their current torpor. If not, the cost-cutting alone may only delay further downside.
Ad
Valneva Stock: New Analysis - 14 June
Fresh Valneva information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
